Mayinglong Pharmaceutical Group Co Ltd (600993) — Cash Flow Reinvestment Rate
Mayinglong Pharmaceutical Group Co Ltd (600993) has a Cash Flow Reinvestment Rate of 0.10x as of September 2025, reinvesting CN¥13.73 Million (capex CN¥13.73 Million ) from operating cash flow of CN¥139.20 Million. Explore Mayinglong Pharmaceutical Group Co Ltd (600993) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Mayinglong Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate (2003–2025)
Historical reinvestment intensity for Mayinglong Pharmaceutical Group Co Ltd across 22 annual periods. Also explore Mayinglong Pharmaceutical Group Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Mayinglong Pharmaceutical Group Co Ltd (2003–2025)
Year-by-year capital reinvestment analysis for Mayinglong Pharmaceutical Group Co Ltd. For live market cap and broader valuation context, see 600993 market cap.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.44x | CN¥862.67 Million | CN¥600.44 Million | CN¥119.37 Million | ▲ +170.2% |
| 2024 | 0.53x | CN¥264.57 Million | CN¥497.61 Million | CN¥203.85 Million | ▼ -53.9% |
| 2023 | 1.15x | CN¥696.64 Million | CN¥604.07 Million | CN¥248.36 Million | ▼ -43.2% |
| 2022 | 2.03x | CN¥693.77 Million | CN¥341.85 Million | CN¥75.01 Million | ▲ +1091.8% |
| 2021 | 0.17x | CN¥101.69 Million | CN¥597.17 Million | CN¥65.10 Million | ▼ -86.8% |
| 2020 | 1.29x | CN¥365.76 Million | CN¥282.99 Million | CN¥45.41 Million | ▲ +746.3% |
| 2019 | 0.15x | CN¥75.07 Million | CN¥491.58 Million | CN¥46.36 Million | ▼ -28.2% |
| 2018 | 0.21x | CN¥65.52 Million | CN¥308.24 Million | CN¥24.96 Million | ▼ -43.1% |
| 2017 | 0.37x | CN¥133.13 Million | CN¥356.17 Million | CN¥41.91 Million | ▼ -74.6% |
| 2016 | 1.47x | CN¥352.23 Million | CN¥239.60 Million | CN¥65.24 Million | ▼ -5.7% |
| 2015 | 1.56x | CN¥285.18 Million | CN¥182.85 Million | CN¥123.93 Million | ▲ +63.0% |
| 2014 | 0.96x | CN¥106.87 Million | CN¥111.67 Million | CN¥106.87 Million | ▲ +48.6% |
| 2013 | 0.64x | CN¥83.68 Million | CN¥129.94 Million | CN¥83.68 Million | ▲ +232.8% |
| 2012 | 0.19x | CN¥32.75 Million | CN¥169.25 Million | CN¥32.75 Million | ▼ -67.4% |
| 2011 | 0.59x | CN¥44.69 Million | CN¥75.37 Million | CN¥44.69 Million | ▲ +266.9% |
| 2009 | 0.16x | CN¥34.93 Million | CN¥216.11 Million | CN¥34.93 Million | ▼ -49.5% |
| 2008 | 0.32x | CN¥32.84 Million | CN¥102.59 Million | CN¥32.84 Million | ▼ -91.6% |
| 2007 | 3.80x | CN¥24.65 Million | CN¥6.49 Million | CN¥24.65 Million | ▲ +1242.0% |
| 2006 | 0.28x | CN¥21.32 Million | CN¥75.27 Million | CN¥21.32 Million | ▼ -54.0% |
| 2005 | 0.62x | CN¥35.95 Million | CN¥58.43 Million | CN¥35.95 Million | ▲ +15.2% |
| 2004 | 0.53x | CN¥28.94 Million | CN¥54.19 Million | CN¥28.94 Million | ▲ +148.1% |
| 2003 | 0.22x | CN¥14.54 Million | CN¥67.52 Million | CN¥14.54 Million | — |